Raybow is a division of Jiuzhou Pharmaceutical. Raybow is a CDMO with headquarters located in Linhai, Taizhou City in Zhejiang Province, China. The division has more than 2000 employees. When combined with Juizhou we have 4800+ employees. Raybow has passed official audits from the USFDA, CFDA and AIFA/PMDA in recent years. Raybow is a leader in green chemical production and manufacturing. Our Taizhou and Suzhou sites have advanced environmental protection treatment systems. This includes a complete set of waste solutions to treat waste liquids, solids and gas. Our equipment allows us to reuse and recirculate certain chemicals used in Pharmaceutical production after they are treated, going a long way to minimize our impact on the environment. Our R&D team is resourceful and has multi-field experienced from an international team of scientists. The team includes 550+ experienced chemists, who provide our customers with professional solutions for CDMO projects. Raybow is committed to the research and development of new pharmaceutical technology, especially in the area of flow chemistry, high-end fluorine chemistry, asymmetric chiral synthesis, glycosides and biological enzyme technology. Raybow has manufacturing sites in both Taizhou and Suzhou in China with a second Taizhou site under construction. Raybow has 2 modern R&D facilities in China - one in Hangzhou which is currently being expanded and a second center in Taizhou. Both facilities feature the latest in lab equipment and ample space. In 2019 Raybow added manufacturing and R&D facilities in the United States with the acquisition of PharmAgra Labs. (Now Raybow USA, Inc.) in Brevard, North Carolina. A new pilot plant was recently completed at the site. A second site in Brevard is under construction and will add another 50 fume hoods and a kilo lab. The company has business offices in Denmark and Germany serving Europe and offices in California and Pennsylvania serving North America.